Jevtana's Toxicity Profile Makes It a Good Option in Metastatic Prostate Cancer

October 9, 2019
Dr. Arash Rezazadeh Kalebasty

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.

At the European Society of Medical Oncology (ESMO) Congress 2019, CURE spoke with Dr. Arash Rezazadeh Kalebasty, a medical oncologist at Norton Cancer Institute, about the results of the trial and what Jevtana offers patients with metastatic castration-resistant prostate cancer.

Transcript:

One important outcome was the grade 3 and higher toxicities were not really very much higher than in the androgen-targeted therapy arm. I think this is very encouraging because in this population, toxicity matters. A lot of patients are elderly.

The specifics for this trial did exclude patients who were not a good candidate for chemotherapy anyway, but we have to be careful about the benefit versus risk when we offer patients chemotherapy as well.

Related Content:

CURE TV

x